US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.99

-2.2085-4.89%

Post-market: 42.990.00000.00%16:10 EDT

Volume:3K

Turnover:133.25K

Market Cap:32.24M

PE:- -

High:45.58

Open:45.58

Low:42.95

Close:45.20

52wk High:45.58

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.12

T/O Rate:0.40%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)

Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

Benzinga Earnings

Natera up over 19%, on Pace for Record High Close

Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?

Simply Wall St.

Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline

Natera, Inc. : Canaccord Genuity Raises Target Price to $375 from $330

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)

Natera, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Natera Q2 FY26 Net Loss Narrows 33.65% to $67 Million; Revenue Rises 37.7% to $752.8 Million

Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Natera Q2 EPS USD -0.47

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring

Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289

THOMSON REUTERS

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Agenus Q2 Revenue Rises on Access and Royalty Income

Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million

Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/HELX/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.9867,"timestamp":1791316800000,"preClose":45.1952,"halted":0,"volume":3036,"hourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"delay":0,"changeRate":-0.04886580875845224,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":-2.2085,"latestTime":"10-06 17:49:53 EDT","open":45.58,"high":45.58,"low":42.95,"amount":133250,"amplitude":0.058192,"askPrice":46.98,"askSize":1,"bidPrice":22.47,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791331200000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":45.1952,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003362,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"volumeRatio":0.119903,"impliedVol":0.1194,"impliedVolPercentile":0.4183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.119903,"shares":750000,"dividePrice":0.1445,"high":45.58,"amplitude":0.058192,"preClose":45.1952,"low":42.95,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.9867,"committee":0.980198,"eps":0,"divideRate":0.003362,"volume":3036,"delay":0,"ttmEps":0,"open":45.58,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.4008,"twentyDayClose":41.6426,"sixtyDayClose":39.7282},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657663625","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663625?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:40","pubTimestamp":1786131636,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND), AMN Healthcare Services (AMN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","BK4588","HELX","BK4581","BK4200","LGND","BK4196","BK4585","BK4139","IE0009354923.USD","WRBY","BK4007","XLV","LABU","XBI","LU1559883803.SGD","AMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657235366","title":"Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657235366","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657235366?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:35","pubTimestamp":1786127721,"startTime":"0","endTime":"0","summary":"Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/08/61052706/natera-ceo-says-company-is-clearly-on-a-roll-after-record-test-volumes-raises-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU2065731478.USD","LU2264538146.SGD","LU0345770308.USD","LU2065169927.USD","LU2324357040.USD","LU0106261612.USD","LU0963586101.USD","LU0012050646.USD","GNOM","LU2065171402.SGD","LU1988902786.USD","BK4139","LU2065171311.SGD","NTRA","LU1064131342.USD","HELX","LU2065170008.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657362840","title":"Natera up over 19%, on Pace for Record High Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2657362840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657362840?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:53","pubTimestamp":1786125180,"startTime":"0","endTime":"0","summary":"Natera, Inc.  is currently at $317.76, up $52.39 or 19.74%--Would be new all-time closing high --On pace for largest percent increase since May 7, 2020, when it rose 21.37%--Snaps a two day losing streak--Up 18.68% this week; best weekly performance since the week ending March 1, 2024, when it rose 26.89%--Up 18.68% month-to-date--Up 38.71% year-to-date--Up 109.12% from 52 weeks ago , when it closed at $151.95--Would be a new 52-week closing high--Up 109.12% from its 52-week closing low of $151.95 on Aug. 8, 2025--Traded as high as $322.00; new all-time intraday high --Up 21.33% at today's intraday high; largest intraday percent increase since Nov. 13, 2024, when it rose as much as 24.18%All data as of 1:50:36 PM ETSource: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0106261612.USD","LU0345770308.USD","NTRA","LU0053671581.USD","LU0012050646.USD","LU1988902786.USD","HELX","LU0345770993.USD","LU0963586101.USD","LU1064131342.USD","BK4139","LU2324357040.USD","LU2065731478.USD","LU2065171402.SGD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619974","title":"Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619974","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619974?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:37","pubTimestamp":1786088256,"startTime":"0","endTime":"0","summary":"Why Ligand Pharmaceuticals Stock Is Back In Focus After Q2 Results\nLigand Pharmaceuticals (LGND) is back on investor radar after Q2 2026 earnings, a completed royalty acquisition, fresh zero coupon convertible financing, and updated full year guidance released on August 6.\nSee our latest analysis for Ligand Pharmaceuticals.\nThe share price reaction to Ligand Pharmaceuticals' Q2 announcement has been mixed, with a 1 day share price return of a 0.8% decline and a 30 day share price return down...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-posts-strong-q2-results-is-the-u","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-posts-strong-q2-results-is-the-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0566484027.USD","HELX","BK4007","BK4139","IE0009354923.USD","LU1559883803.SGD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369495","title":"Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:11","pubTimestamp":1786083103,"startTime":"0","endTime":"0","summary":"An update from Oxford BioMedica ( ($GB:OXB) ) is now available. Oxford Biomedica, a specialist cell and gene therapy CDMO, reported around 9% reven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","HELX","BK4585","BK4588","WDNA","JDOC","OXM","CNCR","IBBQ","FBT","GNOM","IBB","LFSC","SYNB","IDNA","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699263","title":"Natera, Inc. : Canaccord Genuity Raises Target Price to $375 from $330","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699263?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:36","pubTimestamp":1786081006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0345770993.USD","LU2065731478.USD","LU2264538146.SGD","LU0345770308.USD","LU2065169927.USD","LU2324357040.USD","LU0106261612.USD","LU0963586101.USD","LU0012050646.USD","GNOM","LU2065171402.SGD","LU1988902786.USD","BK4139","LU2065171311.SGD","NTRA","LU1064131342.USD","HELX","LU2065170008.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699655","title":"Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:20","pubTimestamp":1786080009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR) and Natera (NTRA) with bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065731478.USD","IMCR","LU2065171402.SGD","LU2065171311.SGD","NTRA","HELX","BK4139","LU2324357040.USD","LU2065170008.USD","LU0053671581.USD","LU0106261612.USD","LU1064131342.USD","LU0012050646.USD","LU0345770993.USD","LU2065169927.USD","LU1988902786.USD","LU0963586101.USD","GNOM","LU0345770308.USD","BK4505","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663010","title":"Natera, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663010?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:02","pubTimestamp":1786050125,"startTime":"0","endTime":"0","summary":"Natera, Inc. reports results for the quarter ended June 30 - Earnings SummaryNatera, Inc.NTRA.OQreported a quarterly adjusted loss of 47 cents per share for the quarter ended June 30, higher than the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0345770308.USD","LU0345770993.USD","LU2065171402.SGD","LU2065169927.USD","GNOM","LU2264538146.SGD","LU2065731478.USD","LU0963586101.USD","LU2065170008.USD","LU1988902786.USD","NTRA","LU2324357040.USD","LU0053671581.USD","LU0012050646.USD","LU2065171311.SGD","HELX","LU0106261612.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657415668","title":"Natera Q2 FY26 Net Loss Narrows 33.65% to $67 Million; Revenue Rises 37.7% to $752.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657415668","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657415668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:35","pubTimestamp":1786048552,"startTime":"0","endTime":"0","summary":"Natera Q2 FY26 net loss narrows 33.65% to $67 million; revenue rises 37.7% to $752.8 millionNatera posted Q2 2026 revenue of USD 752.8 million, up 37.7% year over year.Net loss narrowed to USD 67 mill","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7Zqsnw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065171402.SGD","LU0345770308.USD","GNOM","LU0106261612.USD","BK4139","LU1988902786.USD","LU2264538146.SGD","LU0053671581.USD","LU0345770993.USD","HELX","NTRA","LU2065169927.USD","LU1064131342.USD","LU0963586101.USD","LU0012050646.USD","LU2065171311.SGD","LU2065170008.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650498","title":"Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650498","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650498?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:21","pubTimestamp":1786047704,"startTime":"0","endTime":"0","summary":"Natera Q2 revenue rises beats estimates on higher overall test volumes, raises 2026 outlookOverviewGenetic testing firm's Q2 revenue grew 38%, beating analyst expectationsCompany raised 2026 annual re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","BK4104","LU0106261612.USD","PSNL","LU1988902786.USD","LU0053671581.USD","LU2065169927.USD","NTRA","LU2065170008.USD","BK4139","CAI","LU2065171402.SGD","GNOM","LU2264538146.SGD","LU0345770993.USD","LU0012050646.USD","LU2324357040.USD","LU0963586101.USD","BK4121","LU2065171311.SGD","LU1064131342.USD","HELX","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4007","IHE","KYMR","HELX","LU0566484027.USD","FFOX","LU0053671581.USD","LGND","LU1559883803.SGD","BK4139","PBE","IE0009354923.USD","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657601","title":"Natera Q2 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657601","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657601?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046762,"startTime":"0","endTime":"0","summary":"BRIEF-Natera Q2 EPS USD -0.47Aug 06 (Reuters) - Natera Q2 revenue USD 752.8 million vs. IBES estimate USD 660.7 million.Q2 income from operations USD -75.8 millionQ2 operating expenses USD 555.3 millionQ2 net income USD -67 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXW22CMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0012050646.USD","LU2065171402.SGD","LU2324357040.USD","LU0106261612.USD","NTRA","LU0053671581.USD","LU2065169927.USD","LU2065171311.SGD","GNOM","LU2264538146.SGD","BK4139","LU1988902786.USD","LU2065170008.USD","HELX","LU2065731478.USD","LU0345770308.USD","LU1064131342.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365692","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365692?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:40","pubTimestamp":1786034422,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND), Protagonist Therapeutics (PT...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-protagonist-therapeutics-ptgx-and-zoetis-zts-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-protagonist-therapeutics-ptgx-and-zoetis-zts-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2028103732.USD","LU2089283258.USD","LU2111349929.HKD","LU1236620834.HKD","LU0079474960.USD","PAWZ","LU1721429402.USD","LU0128526141.USD","LU1941712264.USD","LU1941712348.USD","LU1721429741.USD","LU2308191902.HKD","LU0107464264.USD","LU1059921491.USD","LABU","XLV","BK4581","LU0158827948.USD","LGND","LU0345774631.USD","LU1236620750.USD","ZTS","LU2023251221.USD","LU0289739699.SGD","LU2089284900.SGD","BK4137","BK4585","LU0566484027.USD","LU0058720904.USD","BK4588","LU0471298694.HKD","BK4139","LU2271345857.HKD","PTGX","LU0158827781.USD","LU1559883803.SGD","BK4007","BK4534","HCSG","LU0471298777.SGD","HELX","LU0345774391.USD","LU2360106947.USD","XBI","IE00B19Z9505.USD","GB00BDT5M118.USD","LU0029874061.USD","IE0009354923.USD","LU0385154629.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657188656","title":"Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2657188656","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657188656?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:39","pubTimestamp":1786034367,"startTime":"0","endTime":"0","summary":"Natera Inc. ($NTRA) announced an update on their ongoing clinical study. The SCORE-NHL study, officially titled “Sample Collection for Ongoing Rese...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nateras-score-nhl-study-builds-long-term-value-in-lymphoma-monitoring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nateras-score-nhl-study-builds-long-term-value-in-lymphoma-monitoring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","LU0053671581.USD","HELX","NTRA","LU2065731478.USD","LU0012050646.USD","LU2065170008.USD","LU0106261612.USD","BK4139","LU0345770308.USD","LU1064131342.USD","LU2065171311.SGD","LU0963586101.USD","LU2324357040.USD","GNOM","LU1988902786.USD","LU0345770993.USD","LU2264538146.SGD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657392655","title":"Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289","url":"https://stock-news.laohu8.com/highlight/detail?id=2657392655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657392655?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:59","pubTimestamp":1786031999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nAZN4TC72M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009354923.USD","LU0566484027.USD","BK4007","LGND","LU1559883803.SGD","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653875","title":"Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653875?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:12","pubTimestamp":1786029141,"startTime":"0","endTime":"0","summary":"Cancer drugmaker Genmab's H1 revenue rises, lifts FY outlookOverviewDenmark biotech firm's H1 2026 revenue rose 25% yr/yr, driven by higher royalties and salesOperating profit for H1 2026 increased sl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","XNCR","BK4139","LU0566484027.USD","IE0009354923.USD","BK4007","LGND","LU1559883803.SGD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632403","title":"Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632403","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632403?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings SummaryLigand Pharmaceuticals IncorporatedLGND.OQreported quarterly adjusted earnings of $2.37 per share fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4139","IE0009354923.USD","LGND","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635177","title":"Agenus Q2 Revenue Rises on Access and Royalty Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635177","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635177?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:44","pubTimestamp":1786016679,"startTime":"0","endTime":"0","summary":"Agenus Q2 revenue rises on access and royalty incomeOverviewImmuno-oncology drug developer's Q2 revenue rose yr/yr, driven by higher royalty and access program revenueAgenus completed $85 mln private ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND","HELX","XNCR","AGEN","IE0009354923.USD","RCUS","LU1559883803.SGD","BK4007","BK4139","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638485","title":"Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638485","media":"Reuters","labels":["shareholding","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638485?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:09","pubTimestamp":1786014590,"startTime":"0","endTime":"0","summary":"Ligand Q2 FY26 adjusted EPS climbs 48% to $2.37; revenue rises 34% to $63.7 millionLigand Pharmaceuticals posted Q2 GAAP net income of $48.51 million, or $2.22 per diluted share, versus $4.85 million,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3CnHjm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGND","LU1559883803.SGD","BK4007","IE0009354923.USD","LU0566484027.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657902633","title":"Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657902633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657902633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","BK4139","IE0009354923.USD","LGND","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}